Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.

Briefings in bioinformatics - 27 Mar 2024

Ding Xiao-Hong, Xiao Yi, Chen Fenfang, Liu Cheng-Lin, Fu Tong, Shao Zhi-Ming, Jiang Yi-Zhou

Abstract excerpt

Breast cancer is a highly heterogeneous disease with varied subtypes, prognoses and therapeutic responsiveness. Human leukocyte antigen class I (HLA-I) shapes the immunity and thereby influences the outcome of breast cancer. However, the implications of HLA-I variations in breast cancer remain poorly understood. In this study, we established a multiomics cohort of 1156 Chinese breast cancer patients for HLA-I...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Colorectal Neoplasms
Share to Gene Expression Profiling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histocompatibility Antigens Class I

Share to Mutation

Share to Neoplastic Syndromes, Hereditary

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38602320
DOI: 10.1093/bib/bbae151
PMCID: PMC11007120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.PMID 38602320Read ↗

Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.Semantic proximity Read ↗

Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypes.Semantic proximity Read ↗

Clustering of HR+/HER2- breast cancer in an Asian cohort is driven by immune phenotypesSemantic proximity Read ↗

Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response.Semantic proximity Read ↗

The prevalence of HLA-I LOH in Chinese pan-cancer patients and genomic features of patients harboring HLA-I LOHSemantic proximity Read ↗

Pan-Cancer HLA Gene-Mediated Tumor Immunogenicity and Immune EvasionSemantic proximity Read ↗

Pan-cancer HLA Gene-mediated Tumor Immunogenicity and Immune EvasionSemantic proximity Read ↗

HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.Semantic proximity Read ↗

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.Semantic proximity Read ↗

A novel immune checkpoint-related signature for prognosis and immune analysis in breast cancer.Semantic proximity Read ↗

HINS: HLA-mediated immunogenic neoantigen score for robust prediction of immune checkpoint blockade responseSemantic proximity Read ↗

Prognostic Analysis of Patients with Breast Cancer Based on Tumor Mutational Burden, DNA Damage Repair Genes, and Immune InfiltrationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.